Cargando…
Outcome selection for tissue-agnostic drug trials for immune-mediated inflammatory diseases: a systematic review of core outcome sets and regulatory guidance
BACKGROUND: (i).. Identify and map core outcome sets (COS), across 11 immune-mediated inflammatory diseases (IMIDs) in order to facilitate the selection of relevant outcomes across the conditions for innovative trials of tissue-agnostic drug therapies. (ii).. Compare outcomes or endpoints recommende...
Autores principales: | Aiyegbusi, Olalekan Lee, di Ruffano, Lavinia Ferrante, Retzer, Ameeta, Newsome, Philip N., Buckley, Christopher D., Calvert, Melanie J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761289/ https://www.ncbi.nlm.nih.gov/pubmed/35033186 http://dx.doi.org/10.1186/s13063-022-06000-w |
Ejemplares similares
-
Development of a core outcome set and identification of patient-reportable outcomes for primary brain tumour trials: protocol for the COBra study
por: Retzer, Ameeta, et al.
Publicado: (2022) -
Development of a core outcome set for use in adult primary glioma phase III interventional trials: A mixed methods study
por: Retzer, Ameeta, et al.
Publicado: (2023) -
Systematic review of guidance for the collection and use of patient-reported outcomes in real-world evidence generation to support regulation, reimbursement and health policy
por: Maruszczyk, Konrad, et al.
Publicado: (2022) -
Patient-reported outcomes: central to the management of COVID-19
por: Aiyegbusi, Olalekan Lee, et al.
Publicado: (2020) -
Development of a core outcome set for use in community-based bipolar trials—A qualitative study and modified Delphi
por: Retzer, Ameeta, et al.
Publicado: (2020)